Anson Funds Management’s Rosetta Genomics ROSG Stock Holding History
Bought
Maintained
Sold
Other funds holding ROSG
HCM
ICAS
Anson Funds Management's ROSG Position: Q1 2016 in Review
Anson Funds Management sold out of Rosetta Genomics (ROSG) in Q1 2016, closing a stake of 22,879 shares — an estimated $338K sold.
Anson Funds Management first reported a position in ROSG in Q4 2014 and held it in 2 quarters. The position peaked at $338K in Q4 2015. 10 funds tracked by Wall St. Rank hold ROSG as of Q1 2016.
- Anson Funds Management reported no remaining Rosetta Genomics position as of Q1 2016 after selling out during the quarter.
- Anson Funds Management sold 22,879 Rosetta Genomics shares in Q1 2016, an estimated $338K.
- Anson Funds Management first reported a position in Rosetta Genomics in Q4 2014 and held it in 2 quarters.
- Anson Funds Management's Rosetta Genomics position peaked at $338K in Q4 2015.
- 10 funds tracked by Wall St. Rank held Rosetta Genomics as of Q1 2016.
Based on Anson Funds Management's 13F filing for Q1 2016, filed 13 May 2016.